ACADACADIA Pharmaceuticals Inc.
$19.78-19% 1Y
$19.78
$19.5752 weeks$30.58
The financials
ACADIA Pharmaceuticals Inc. by the numbers
ACADIA Pharmaceuticals Inc. (ACAD) reported revenue of $308M in Q2 2026 (quarter ended Jun 30, 2026), up 16% from the same quarter a year earlier. That came with a gross margin of 91% and net income of $32M (10% of revenue). For the full year FY2025, revenue was $1.07B (+12% year on year) and net income $391M. Its largest product in Q2 2026 was Nuplazid at $183M, 59% of the disclosed total, ahead of Daybue at 41%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $308M | $265M | +16% |
| Gross profit | $280M | $244M | +15% |
| Operating income | $38M | $32M | +17% |
| Net income | $32M | $27M | +18% |
| Diluted EPS | $0.18 | $0.16 | +13% |
| Product | Revenue | Share |
|---|---|---|
| Nuplazid | $183M | 59% |
| Daybue | $125M | 41% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $308.0M (+15%)
Daybue grew +30% year on yearNuplazid +8.7% year on year
Segment Latestquarter on quarteryear on year
- Nuplazid$183.1M$183.1Mquarter on quarter +9.7%year on year +8.7%+9.7%+8.7%
- Daybue$124.8M$124.8Mquarter on quarter +23%year on year +30%+23%+30%